Abstract
Chemotherapy is not effective for hepatocellular carcinoma (HCC). HMG-CoA redutase inhibitors have cytostatic activity for cancer cells, but their clinical usefulness is unknown. To investigate whether pravastatin, a potent HMG-CoA reductase inhibitor, prolongs survival in patients with advanced HCC, this randomized controlled trial was conducted between February 1990 and February 1998 at Osaka University Hospital. 91 consecutive patients <71 years old (mean age 62) with unresectable HCC were enroled in this study. 8 patients were withdrawn because of progressive liver dysfunction; 83 patients were randomized to standard treatment with or without pravastatin. All patients underwent transcatheter arterial embolization (TAE) followed by oral 5-FU 200 mg–1d for 2 months. Patients were then randomly assigned to control (n = 42) and pravastatin (n = 41) groups. Pravastatin was administered at a daily dose of 40 mg. The effect of pravastatin on tumour growth was assessed by ultrasonography. Primary endpoint was death due to progression of HCC. The duration of pravastatin administration was 16.5 ± 9.8 months (mean ± SD). No patients in either group were lost to follow-up. Median survival was 18 months in the pravastatin group versus 9 months in controls (P = 0.006). The Cox proportional hazards model showed that pravastatin was a significant factor contributing to survival. Pravastatin prolonged the survival of patients with advanced HCC, suggesting its value for adjuvant treatment. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Byington KP, Jukema JW, Salonen JT, Bertram P, Bruscheke AV, Hoen H, Furberg CD and Mancini GBJ (1995) Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 92: 2419–2425
Cavalli F, Rozencweig M, Goldhirsch A and Hansen HH (1981) Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol 17: 1079–1082
Charnsagavej S, Chuang VP, Wallace S, Soo CS and Bowers T (1983) Transcatheter management of promary carcinoma of the liver. Radiology 147: 51–55
Coi TK, Lee NW and Wong J (1984) Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 53: 401
Di Bisceglie AM (1995) Hepatitis C and hepatoecllular carcinoma. Seminar Liver Dis 15: 64–69
El-Serag HB and Mason AC (1999) Rising incidence of heptocellular carcinoma in the United States. N Engl J Med 340: 745–750
Falkson G, MacIntyre JM, Moertel CG, Johnson LA and Scherman RC (1984) Primary liver cancer: An Eastern JM Cooperative Oncology Group Trial. Cancer 54: 970–977
Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl NE and Oliff A (1993) Selective inhibition of farnesyl: transferase blocks ras processing in vivo. J Biol Chem 268: 7617–7620
Goldstein JL and Brown MS (1990) Regulation of the mevalonate pathway. Nature 343: 425–430
Goldstein JL, Helgeson JAS and Brown MS (1979) Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptors. J Biol Chem 254: 5403–5409
Habenicht AJR, Glomset JA and Ross R (1980) Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 255: 5134–5140
James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD and Marsters, Jr JC (1993) Benzodiazepine peptidomimetics: protein inhibitor of ras farnesylation in animal cells. Science 260: 1937–1942
Kandutsch AA and Chen HW (1979) Consequences of blocked sterol synthesis in cultured cells, DNA synthesis and membrane composition. J Biol Chem 252: 409–415
Kawata S, Takaishi K, Nagase T, Ito N, Tamura S, Matsuzawa Y and Tarui S (1990) Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: Possible mechanism for alteration of cholesterol biosynthesis. Cancer Res 50: 3270–3273
Koga T, Kawabata K, Arai K, Matsushima N, Koike H, Komai T, Rei M and Nakamura H (1995) Comparative pharmacokinetics of pravastatin and simvastatin. Bull Mol Biol Med 20: 103–105
Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A and Gibbs JB (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934–1937
Maltese WA, Defendini R, Green RA, Sheridan KM and Donley DK (1985) Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Clin Invest 76: 1748–1754
Matsuda Y, Kawata S, Nagase T, Maeda Y, Yamasaki E, Kiso S, Ishiguro H and Matsuzawa Y (1994) Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Cancer 73: 53–57
Okuda K (1992) Hepatocellular carcinoma: recent progress. Hepatology 15: 948–963
Okuda K, Fujimoto I, Hanai A and Urano Y (1987) Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 47: 4967–4972
Shepherd J, Lobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, Mackillop JH and Packard CJ for the West of Scotland Coronary Prevention Study Group (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301–1307
Simonetti RG, Camma C, Fiorello F, Politi F, D’amico G and Pagliaro L (1991) Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 36: 962–972
Sinensky M, Beck LA, Leonard S and Evans R (1990) Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 265: 19937–19941
Stebolt-Leopold JS, Dudley DT, Herrera R, Becelaere KV, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR and Saltiel AR (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med 5: 810–816
Stefanini GF, Amorati P, Beselli M, Mucci F, Celi A, Arienti V, Roversi R, Rossi C, Re G and Gasbarrini G (1995) Efficacy of transarterial targeted treatment on survival of patients with hepatocellular carcinoma. Cancer 75: 2427–2434
The Liver Cancer Study Group of Japan (1989) The general rules of the clinical and pathological study of primary liver cancer. Jpn J Sur 19: 98–129
Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M, Matsuda H, Tarumi C, Watanabe Y and Fujii S (1986) CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibiton of sterol synthesis and hypolipidemic effect on various animal species. Biophys Biochem Acta 877: 50–60
Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K and Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397–401
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kawata, S., Yamasaki, E., Nagase, T. et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84, 886–891 (2001). https://doi.org/10.1054/bjoc.2000.1716
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1716
Keywords
This article is cited by
-
The Role of Statins in Cirrhosis
Current Treatment Options in Gastroenterology (2022)
-
Statins: a repurposed drug to fight cancer
Journal of Experimental & Clinical Cancer Research (2021)
-
Concurrent use of statins and neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis
International Journal of Colorectal Disease (2021)
-
Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs
Current Oncology Reports (2021)
-
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis
Hepatology International (2021)